1732-P: Liraglutide Ameliorates Diabetic Cardiomyopathy via Ferroptosis Inhibition: Clinical CMR Evidence and Mechanistic Insights
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-1732-p ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von LIANQIN CHEN und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: We investigated Liraglutide's (LIRA) effect on diabetic myocardial fibrosis via cardiac magnetic resonance (CMR) in patients and ferroptosis mechanisms in mice.
Methods
T2DM patients (n=17) were randomized to LIRA or Insulin for 24 weeks. Cardiac function and diffuse fibrosis (native T1 mapping) were quantified by CMR. In parallel, T2DM mice received LIRA for 8 weeks. Myocardial fibrosis (Masson staining), mitochondrial ultrastructure (TEM), and ferroptosis markers (GPX4, XCT, PTGS2) were analyzed.
Results
Clinical: As shown in Table 1, LIRA significantly improved metabolic profiles (Weight and LDL-C) compared to Insulin, alongside effective glycemic control. Crucially, CMR revealed that LIRA increased LVEF and reduced LVMI, MVR, and native T1 values, indicating reversed myocardial remodeling and alleviated diffuse fibrosis. The Insulin group showed no significant cardiac structural improvements. Preclinical: In T2DM mice, LIRA reduced collagen deposition and restored mitochondrial integrity. Mechanistically, LIRA inhibited ferroptosis by significantly upregulating GPX4 and XCT protein expression (P<0.01) and suppressing PTGS2, thereby mitigating iron-dependent oxidative damage.
Conclusion
Beyond effective glycemic control, Liraglutide confers superior metabolic benefits and reverses myocardial fibrosis and dysfunction in T2DM, mechanisms partially driven by ferroptosis inhibition. Disclosure L. Chen: None. Y. Lv: None. Y. Lin: None. P. Yu: None. Funding National Natural Science Foundation of China - General Projects (No.82570828), National Key Research and Development Program of China (No.2024YFC3607400), Tianjin Health Research Project (No.TJWJ2025RC005), Tianjin Institute of Urology talent funding program (No.MYSRC2024), First Level Leading Talent Project of “123 Climbing Plan” for Clinical Talents of Tianjin Medical University, “Tianjin Medical Talents” project, the second batch of high-level talents selection project in health industry in Tianjin (No.TJSJMYXYC-D2-014), Key Project of Natural Science Foundation of Tianjin (No.22JCZDJC00590), Tianjin Key Medical Discipline (Specialty) Construct Project (No.TJYXZDXK-032A), Tianjin Key Medical Discipline Construction Project (No.TJYXZDXK-3-007B), Tianjin Key Cultivation Medical Discipline Construction Project (No.TJYXZDXK-3-018C).
Zitieren
APA
CHEN, L., LV, Y., LIN, Y., & YU, P. (2026). 1732-P: Liraglutide Ameliorates Diabetic Cardiomyopathy via Ferroptosis Inhibition: Clinical CMR Evidence and Mechanistic Insights. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1732-p
Vancouver
CHEN L, LV Y, LIN Y, YU P. 1732-P: Liraglutide Ameliorates Diabetic Cardiomyopathy via Ferroptosis Inhibition: Clinical CMR Evidence and Mechanistic Insights. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1732-p
BibTeX
@article{CHEN2026,
author = {CHEN, LIANQIN and LV, YINGQI and LIN, YAO and YU, PEI},
title = {1732-P: Liraglutide Ameliorates Diabetic Cardiomyopathy via Ferroptosis Inhibition: Clinical CMR Evidence and Mechanistic Insights},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-1732-p}
}
EUVIMED